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Abstract 
 
Objective: To investigate the potential value of biophysical and biochemical markers at 35-37 
weeks’ gestation in the prediction of adverse perinatal outcome.  
 
Methods: Screening study in 3,953 singleton pregnancies at 35-37 weeks. Estimated fetal 
weight (EFW), uterine artery pulsatility index (PI), umbilical artery PI, fetal middle cerebral 
artery (MCA) PI, mean arterial pressure (MAP), serum placental growth factor (PLGF) and 
soluble fms-like tyrosine kinase-1 (sFlt-1) were measured. The detection rate (DR) and false 
positive rate (FPR) of screening by each biomarker were estimated for preeclampsia, 
delivery of small for gestational age (SGA) neonate, cesarean section for fetal distress 
before or during labor, umbilical arterial cord blood pH <7.0 or umbilical venous blood pH 
<7.1, Apgar score <7 at 5 minutes and admission to the neonatal unit (NNU).  
 
Results: Multivariable regression analysis demonstrated that significant prediction of PE was 
provided by PLGF, sFlt-1 and MAP with DR of 73% at 10% FPR. Prediction of SGA was 
provided by EFW, PLGF and uterine artery PI with DR of 63% at 10% FPR. Prediction of 
cesarean section for fetal distress before labor was provided by EFW and umbilical artery PI 
with DR of 100% at 10% FPR. Prediction of fetal distress in labor was provided by EFW and 
sFlt-1 with DR of 15% at 10% FPR. There were no significant differences from the normal 
outcome group in any of the biomarkers for low cord blood pH, low Apgar score or NNU 
admission. 
 
Conclusion: At 35-37 weeks’ gestation, biomarkers of impaired placentation and fetal 
hypoxemia provide good prediction of PE, SGA and fetal distress before labor, but poor or no 
prediction of adverse events in labor or after birth. 
  
Introduction 
 
Impaired placentation and / or placental dysfunction, reflected in increased pulsatility index 
(PI) in the uterine arteries and reduced serum placental growth factor (PLGF) and increased 
soluble fms-like tyrosine kinase-1 (sFlt-1), are associated with subsequent development of 
preeclampsia (PE) and birth of small for gestational age (SGA) neonates [1-3]. In the 1980’s 
analysis of fetal blood obtained by cordocentesis demonstrated that some SGA fetuses are 
hypoxemic and acidemic and have a metabolic profile compatible with intrauterine starvation 
[4-6]. In SGA fetuses, hypoxemia was associated with increased impedance to flow in the 
uterine and umbilical arteries and reduced impedance in the fetal middle cerebral artery 
(MCA) [7-9]. It was recognized that the majority of fetuses that are growth restricted due to 
uteroplacental insufficiency may not actually be SGA [10] and it was speculated that if the 
biomarkers of fetal hypoxia are as useful in identifying affected fetuses that are not small as 
they are for SGA fetuses, the biomarkers may replace measurement of fetal size for the 
antenatal prediction of fetal asphyxia [7]. 
 
A large screening study at 30-34 weeks’ gestation reported that biomarkers of impaired 
placentation / placental dysfunction and fetal hypoxemia are useful in the prediction of PE 
and birth of SGA neonates [11]. However, the biomarkers provide poor or no prediction of 
adverse events in labor or after birth, including cesarean section for fetal distress, low cord 
blood pH, low Apgar score or neonatal unit (NNU) admission for cases other than those with 
PE and / or SGA [11]. Possible explanations for poor performance of screening at 30-34 
weeks in prediction of adverse events in labor or after birth are firstly, the premise that non 
SGA starved fetuses are as hypoxic as SGA starved fetuses is not true [12], secondly, the 
outcome measures are primarily the consequence of problems which start in labor and 
therefore cannot be predicted using markers of chronic feto-placental hypoxia and thirdly,  
assessment at 30-34 weeks is too remote from events in labor and that assessment at 35-37 
weeks may improve the screening performance for labor related adverse outcomes.   
 
The objective of this screening study is to investigate the potential value of uterine artery PI, 
umbilical artery PI, MCA PI, mean arterial pressure (MAP) and serum PLGF and sFlt-1, at 
35-37 weeks’ gestation, in the prediction of adverse perinatal outcome, including 
development of PE, birth of SGA neonate, cesarean section for fetal distress before or 
during labor, umbilical arterial cord blood pH <7.0 or umbilical venous blood pH <7.1, Apgar 
score <7 at 5 minutes and NNU admission. 
 
 
Methods 
 
The data for this study were derived from prospective screening for adverse obstetric 
outcomes in women attending for their routine hospital visit in the third trimester of 
pregnancy at King’s College Hospital, London and Medway Maritime Hospital, Kent, 
between February 2014 and December 2014. This visit, which was held at 35+0-37+6 
weeks’ gestation, included recording of maternal characteristics and medical history, 
estimation of fetal size from ultrasound measurement of fetal head circumference, abdominal 
circumference and femur length [13], transabdominal Doppler assessment of the uterine 
artery, umbilical artery and fetal MCA PI [14-16], measurement of MAP [17] and serum 
concentration of PLGF and sFlt-1 (Cobas e411 system, Roche Diagnostics, Penzberg, 
Germany). Gestational age was determined by the measurement of fetal crown-rump length 
at 11-13 weeks or the fetal head circumference at 19-24 weeks [13,18].  
 
Written informed consent was obtained from the women agreeing to participate in a study on 
adverse pregnancy outcome, which was approved by the Ethics Committee of each 
participating hospital. The pregnancies included in the study were those with data on all 
eight biomarkers resulting in live birth or stillbirth of phenotypically normal babies at >24 
weeks’ gestation. 
 
Patient characteristics  
 
Patient characteristics recorded included maternal age, racial origin (Caucasian, Afro-
Caribbean, South Asian, East Asian and mixed), method of conception (spontaneous, use of 
ovulation drugs or in vitro fertilization), cigarette smoking during pregnancy, medical history 
of chronic hypertension, diabetes mellitus, systemic lupus erythematosus (SLE) or anti-
phospholipid syndrome (APS) and parity (parous or nulliparous if no previous pregnancies at 
> 24 weeks). Maternal weight and height were measured. 
 
Outcome measures 
 
Data on pregnancy outcome were collected from the hospital maternity records or the 
general medical practitioners of the women. The outcome measures of the study were PE, 
SGA, cesarean section for fetal distress before or during labor, umbilical arterial cord blood 
pH <7.0 or venous blood pH <7.1, Apgar score <7 at 5 minutes and admission to NNU. The 
newborn was considered to be SGA if the birth weight was less than the 10th percentile after 
correction for gestational age at delivery [19]. The definition of PE was that of the 
International Society for the Study of Hypertension in Pregnancy [20].  
 
Statistical analysis 
 
Comparison between the outcome groups was by χ2-test or Fisher’s exact test for 
categorical variables and Mann Whitney-U test for continuous variables. Categorical data 
are presented as n (%) and continuous data as median and interquartile range (IQR).   
 
The measured values of uterine artery PI, umbilical artery PI, MCA PI, MAP, PLGF and sFlt-
1 were expressed as multiple of the median (MoM) after adjustment for variables from 
maternal characteristics and medical history that affect these measurements [21-25]. 
Univariable and multivariable logistic regression analysis was used to determine if log10 MoM 
of each biomarker had a significant contribution in predicting each adverse outcome. The 
detection rate (DR) and false positive rate (FPR) of screening were estimated for each 
adverse outcome. The performance of screening was determined by receiver operating 
characteristic (ROC) curves analysis. 
 
The statistical software package SPSS 22.0 (IBM SPSS Statistics for Windows, Version 
22.0. Armonk, NY: IBM Corp, 2013) was used for the data analyses. 
 
 
Results 
 
Study population 
 
The characteristics of the study population and the various subgroups according to outcome 
are given in Table 1.  
 
Biomarkers in pregnancies with PE or birth of SGA neonates 
 
The median MoM values of biomarkers and percentage of values above or below a 
percentile for pregnancies resulting in PE or birth of SGA neonates are compared to the 
unaffected pregnancies by any one of these adverse outcomes are shown in Table 2. 
 
In the pregnancies that developed PE, compared to the unaffected group, there was higher 
uterine artery PI, MAP and serum sFlt-1 and lower serum PLGF (Table 2). Multivariable 
logistic regression analysis demonstrated that significant contributions to PE were provided 
by MAP, sFlt-1 and PLGF, (AUROC curve 0.913, 95% CI 0.874-0.952). The DR of combined 
screening by all significant contributors was 73.3%, at FPR of 10% (Figure 1). 
 
In the pregnancies with SGA neonates, compared to the unaffected group, there was higher 
uterine artery PI, MAP, umbilical artery PI and MAP and lower EFW and serum PLGF (Table 
2). Multivariable logistic regression analysis demonstrated that significant contributions for 
SGA were provided by EFW, PLGF and uterine artery PI (AUROC curve 0.883, 95% CI 
0.867-0.899). The DR of combined screening by all significant contributors was 62.8%, at 
FPR of 10%, (Figure 1). 
 
Biomarkers in pregnancies with stillbirth 
 
In the study population there was one stillbirth. The interval between assessment and 
delivery was 6.0 weeks. There were no risk factors noted in the maternal demographic 
characteristics as the pregnancy was in a nulliparous woman following a spontaneous 
conception, who was a non-smoker with a maternal body mass index within normal range 
and no maternal medical illness of note with no obstetric complications in the current 
pregnancy. The uterine artery PI, MAP and serum sFlt-1 were below the 95th percentile and 
serum PLGF was more than the 5th precentile. The estimated birth weight z-score was -2.4.  
 
Biomarkers in pregnancies delivered by cesarean section for fetal distress 
 
In the 3,952 pregnancies with live births, there were 3,016 with vaginal delivery following 
spontaneous or induced labor, 436 with elective cesarean section for a variety of indications 
and 500 with cesarean section following spontaneous or induced labor; in the latter group 
the indication for cesarean section was fetal distress in 275 cases. In the elective cesarean 
section group (n=436) there were a variety of indications, including breech or transverse lie 
(n=83), placenta previa (n=22), previous cesarean section, traumatic birth or maternal 
request (n=291), maternal medical disorder (n=33) and SGA fetuses with fetal compromise 
diagnosed by abnormal fetal heart rate patterns or fetal Doppler indices (n=7).  
 
The median MoM values of biomarkers and percentage of values above or below a 
percentile for pregnancies resulting in delivery by cesarean section for fetal distress before 
labor (n=7) and during labor (n=275) or and those delivering vaginally are shown in Table 3.  
 
In the group with cesarean section for fetal distress before labor, compared to those 
delivering vaginally, there was significant alteration in all biomarkers (Table 3).  In the study 
population for assessment of fetal distress in labor, the median interval from assessment to 
delivery was 4.0 weeks (IQR 3.0-4.7). In the group with cesarean section for fetal distress in 
labor, compared to those delivering vaginally, there was higher EFW and serum sFlt-1, but 
no significant differences in median value of the other biomarkers. Multivariable logistic 
regression analysis demonstrated that significant contribution to cesarean section for fetal 
distress was provided by EFW and sFlt-1 (AUROC curve 0.566, 95% CI 0.531-0.601); the 
DR was 15.3%, at 10% FPR (Figure 1).   
 
Biomarkers in pregnancies with adverse outcome after delivery 
 
The median MoM values of biochemical and biophysical markers and percentage of values 
above or below a percentile in pregnancies with and without low cord blood pH, low Apgar 
score at 5 minutes and NNU admission are shown in Table 4. In the group with low cord 
blood pH compared to those with normal pH, in those with low 5 minute Apgar score 
compared to those with normal score, and in those with NNU admission compared to those 
without admission, there were no significant differences in the median MoM values of any of 
the biomarkers.  
 
 
Discussion 
 
Main findings of the study 
 
The findings of this study demonstrate that in pregnancies that develop PE and those that 
result in delivery of SGA neonates there is biophysical and biochemical evidence of impaired 
placentation or placental dysfunction reflected in increased uterine artery PI, MAP and 
serum sFlt-1 and reduced serum PLGF. Screening by a combination of biomarkers at 36 
weeks’ gestation predicts the majority of pregnancies that develop PE and those that deliver 
SGA neonates. 
 
Impaired placentation / placental dysfunction and fetal hypoxemia are also observed in a 
small group of pregnancies with SGA fetuses delivering by elective cesarean section for 
evidence of fetal distress. However, combined screening at 36 weeks is not useful in the 
prediction of fetal distress in labor necessitating delivery by cesarean section, low cord blood 
pH, low Apgar score, or NNU admission. 
 
Strengths and limitations of the study 
 
The strengths of this third-trimester screening study are first, examination of pregnant 
women attending for routine care, second, use of a specific methodology and appropriately 
trained doctors to measure MAP and carry out the Doppler studies, third, use of automated 
machines to prospectively obtain reproducible measurements of serum PLGF and sFlt-1, 
fourth, estimate MoM values for biophysical and biochemical markers after adjustment for 
factors that affect the measurements, and fifth, examination of a wide range of well accepted 
indicators of adverse perinatal outcome. 
 
The main limitation of the study is that the results of the 35-37 weeks’ scan were made 
available to the obstetricians of the patients who would have taken specific actions on further 
monitoring and delivery for the cases of suspected SGA with abnormal Doppler findings. It 
could therefore be argued that the performance of screening for adverse perinatal outcomes 
by biomarkers of impaired placentation and fetal hypoxemia would have been negatively 
biased. It is possible that some of the cases of SGA and fetal distress that were delivered by 
elective cesarean section would have resulted in stillbirth or fetal distress in labor and low 
cord blood pH had they not been detected by the routine assessment at 36 weeks. However, 
the number of these cases was very small and it is therefore unlikely that they would have 
had a major impact on the overall effect of adverse events in labor and after birth. 
 
Comparison with findings from previous studies 
 
The results of this study are compatible with those of the only previous screening study that 
examined biomarkers of impaired placentation / placental dysfunction and fetal hypoxemia at 
30-34 weeks’ gestation and reported that these markers are useful in the prediction of PE 
and birth of SGA neonates, but not of adverse events in labor or after birth [13].  
 
Implications for clinical practice 
 
An integrated clinic at 36 weeks’ gestation, which includes fetal biometry and measurement 
of biomarkers, identifies a high proportion of pregnancies that subsequently develop PE and 
those delivering SGA neonates. It was previously proposed that prediction of most cases of 
term PE and SGA is best achieved by a third-trimester assessment at around 36 weeks’ 
gestation. It was also suggested that such timing of assessment would inevitably miss the 
cases of preterm PE and SGA and it was therefore proposed that these cases should be 
identified at an integrated clinic at 22 weeks and receive close monitoring for early diagnosis 
of PE and / or SGA and appropriate timing of delivery [3,26]. 
 
In pregnancies without SGA or PE, combined screening at 36 weeks is not useful in the 
prediction of adverse events during labor or after birth. It is possible that this finding is the 
consequence of the long delay of about four weeks between assessment and delivery or the 
effects of events in labor and delivery on the outcome measures that overshadow the 
contribution of chronic hypoxia. Alternatively, this finding provides support for the hypothesis 
proposed more than 20 years ago that impaired placentation or placental dysfunction is 
usually not severe enough to cause fetal hypoxia until reduced nutrition has stunted the size 
of the fetus sufficiently to become SGA; consequently, tests of fetal hypoxia would rarely be 
useful when the fetus is growing normally [12]. Research into the causes of morbidity in 
appropriately grown fetuses should perhaps look for pathologies other than chronic fetal 
hypoxia. 
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Figure legends 
 
Figure 1. Receiver operating characteristic curves for prediction of preeclampsia (PE), small 
for gestational age (SGA) neonates and fetal distress resulting in delivery by cesarean 
section before and during labor. 
 
Table 1. Maternal and pregnancy characteristics of the study population and subgroups of preeclampsia, small for gestational age neonates, 
fetal distress before or during labor leading to cesarean section, low umbilical arterial or venous cord blood pH, low 5-minute Apgar score and 
admission to the neonatal unit. In each group the data are compared to the cohort without the outcome measure. 
 
 
All pregnancies 
(n=3,953) 
Preeclampsia 
(n=65) 
Small for gestation 
(n=379) 
Prelabor 
Fetal distress 
(n=7)  
Intrapartum 
fetal distress 
(n=275) 
Low cord pH 
(n=52) 
Low Apgar score 
(n=20) 
NNU admission 
(n=232) 
Maternal characteristics         
Maternal age (years) 37.7 (26.9-35.3) 33.1 (27.8-35.8) 30.0 (25.0-34.3) 25.9 (22.0-38.8) 32.0 (27.0-35.4) 31.6 (27.5-35.3) 29.8 (27.5-34.5) 31.4 (26.3-35.1) 
Maternal weight (Kg) 79.0 (70.9-89.6) 85.0 (77.0-98.9) 73.1 (65.1-82.5) 71.0 (64.3-82.3) 81.6 (73.5-91.5) 78.0 (71.6-87.8) 76.0 (69.2-86.5) 82.2 (72.0-95.0) 
Maternal height (m) 1.64 (1.60-1.69) 1.65 (1.61-1.72) 1.62 (1.58-1.66) 1.59 (1.55-1.63) 1.62 (1.58-1.66) 1.62 (1.59-1.67) 1.62 (1.57-1.65) 1.64 (1.59-1.69) 
Cigarette smoker 365 (9.2) 3 (4.6) 70 (18.5)*** 2 (28.6) 27 (9.8) 5 (9.6) 3 (15.0) 18 (7.8) 
Racial origin         
Caucasian 2921 (73.9) 47 (72.3) 237 (62.5) 4 (57.1) 174 (63.3) 40 (76.9) 17 (85.0) 184 (79.3) 
Afro-Caribbean 679 (17.2) 11 (16.9) 93 (24.5)*** 3 (42.9) 73 (26.5)*** 7 (13.5) 3 (15.0) 39 (16.8) 
South Asian 146 (3.7) 3 (4.6) 29 (7.7) 0 (0.0) 13 (4.7) 4 (7.7) 0 (0.0) 4 (1.7) 
East Asian 87 (2.2) 1 (1.5) 6 (1.6) 0 (0.0) 6 (2.2) 0 (0.0) 0 (0.0) 2 (0.9) 
Mixed 120 (3.0) 3 (4.6) 14 (3.7) 0 (0.0) 9 (3.3) 1 (1.9) 0 (0.0) 3 (1.3) 
Conception         
Spontaneous 3839 (97.1) 59 (90.8) 368 (97.1) 7 (100.0) 263 (95.6) 52 (100.0) 19 (95.0)  225 (97.0) 
Assisted conception 114 (2.9) 6 (9.2) 11 (2.9) 0 (0.0) 12 (4.4) 0 (0.) 1 (5.0) 7 (3.0) 
Medical disorder         
Chronic hypertension 55 (1.4) 5 (7.7)** 6 (1.6) 0 (0.0) 11 (4.0)*** 1 (1.9) 1 (5.0) 9 (3.9)** 
SLE / APS 11 (0.3) 0 (0.0) 1 (0.3) 0 (0.0) 1 (0.4) 0 (0.0) 0 (0.0) 0 (0.0) 
Diabetes mellitus 47 (1.2) 2 (3.1) 1 (0.3) 0 (0.0) 2 (0.7) 0 (0.0) 0 (0.0) 3 (1.3) 
Obstetric history         
Parous 1987 (50.3) 17 (26.2) 146 (38.5) 5 (71.4) 67 (24.4) 16 (30.8) 9 (45.0) 97 (41.8) 
Nulliparous 1966 (49.7) 48 (73.8)*** 233 (61.5)*** 2 (28.6) 208 (75.6)*** 36 (69.2) 11 (55.0) 135 (58.2) 
Pregnancy complication         
Gestational diabetes 115 (2.9) 3 (4.6) 9 (2.4) 0 (0.0) 13 (4.7) 2 (3.8) 0 (0.0) 11 (4.7) 
SROM 201 (5.1) 1 (1.5) 25 (6.6) 0 (0.0) 44 (16.0)*** 4 (7.7) 1 (5.0) 22 (9.5)** 
Labor and delivery         
 
SLE= systemic lupus erythematosus; APS = anti-phospholipid syndrome; SROM = Spontaneous rupture of membranes; VD = vaginal delivery; CS = cesarean 
section; GA = gestational age; EFW = estimated fetal weight; BW = birth weight 
 
Significance value adjusted for multiple comparisons with post hoc Bonferonni correction * = p<0.01; ** = p<0.001 
Spontaneous labor,  VD 2461 (62.3) 3 (4.6) 232 (61.2) 0 (0.0) 0 (0.0) 22 (42.3) 10 (50.0) 116 (50.0) 
Spontaneous labor, CS 303 (7.7) 5 (7.7) 28 (7.4) 0 (0.0) 164 (59.6) 12 (23.1) 2 (10.0) 31 (13.4)** 
Induced labor, VD 556 (14.1) 30 (46.2)*** 70 (18.5) 0 (0.0) 0 (0.0) 7 (13.5) 0 (0.0) 38 (16.4) 
Induced labor, CS 197 (5.0) 14 (21.5)*** 20 (5.3) 0 (0.0) 111 (40.4)*** 6 (11.5) 5 (25.0) 21 (9.1)** 
Elective CS 436 (11.0) 13 (20.0) 29 (7.7) 7 (100.0) 0 (0.0) 5 (9.6) 3 (15.0) 26 (11.2) 
Assessment         
GA at assessment (wks) 36.1 (36.0-36.4) 36.1 (35.9-36.4) 36.1 (36.0-36.6) 36.3 (35.4-36.4) 36.1 (36.0-36.4) 36.3 (36.0-36.4) 36.1 (36.0-36.6) 36.1 (35.9-36.4) 
EFW (percentile) 49.7 (25.7-73.3) 47.8 (26.4-79.4) 12.2 (4.2-24.8) 0.6 (0.3-2.0) 55.5 (29.3-76.2) 50.2 (26.5-73.7) 59.1 (30.8-67.5) 55.5 (28.1-78.6) 
Outcome         
GA at delivery (wks) 40.0 (39.1-40.9) 39.1 (37.4-40.4) 39.9 (39.0-40.9) 37.0 (35.6-37.3) 40.6 (39.6-41.3) 40.4 (39.4-41.0) 40.1 (38.9-40.9) 39.7 (38.5-40.9) 
BW  (percentile) 48.7 (24.4-74.8) 42.7 (19.8-70.8) 5.9 (3.2-8.1) 3.5 (1.8-7.5) 42.1 (17.7-73.3) 39.1 (17.9-63.0) 38.0 (18.5-69.4) 54.9 (21.0-83.0) 
Table 2. Biochemical and biophysical markers in pregnancies resulting in preeclampsia, 
birth of small for gestational age neonates and those unaffected by these adverse outcomes. 
 
 
 
SGA = small for gestational age neonate with birth weight below the 10th percentile. PLGF = placental growth 
factor; sFlt-1  = soluble fms-like tyrosine kinase-1; Ut PI = uterine artery pulsatility index; UA PI = umbilical artery 
pulsatility index; MCA PI = middle cerebral artery pulsatility index; MAP = mean arterial pressure; EFW = 
estimated fetal weight.  Significance value adjusted for multiple comparisons with post hoc Bonferonni correction; 
*p<0.025, ** p<0.01; *** p<0.0001 
 
Unaffected 
(n=3,509) 
Preeclampsia 
(n=65) 
SGA 
(n=379) 
Biochemical markers    
PlGF (MoM), median (IQR) 1.02 (0.59-1.79) 0.34 (0.24-0.48)*** 0.66 (0.37-1.15)*** 
PlGF < 5th percentile, n (%) 132 (3.8) 18 (27.7)*** 48 (12.7)*** 
    
sFlt -1 (MoM), median (IQR) 0.97 (0.73-1.35) 2.08 (1.45-3.24)*** 0.94 (0.71-1.37) 
sFlt > 95th percentile, n (%) 141 (4.0) 29 (44.6)*** 28 (7.4)** 
Biophysical markers    
Ut PI (MoM), median (IQR) 0.97 (0.83-1.15) 1.15 (0.89-1.40)*** 1.06 (0.86-1.29)*** 
Ut PI > 95th percentile, n (%) 150 (4.3) 11 (16.9)*** 37 (9.8)*** 
    
UA PI (MoM), median (IQR) 1.00 (0.90-1.13) 0.99 (0.89-1.10) 1.07 (0.97-1.18)*** 
UA PI > 95th percentile, n (%) 147 (4.2) 3 (4.6) 48 (12.7)*** 
    
MCA PI (MoM), median (IQR) 1.01 (0.90-1.13) 0.96 (0.87-1.11) 0.99 (0.89-1.11) 
MCA PI < 5th percentile, n (%) 169 (4.8) 7 (10.8) 22 (5.8) 
    
MAP (MoM), median (IQR) 1.00 (0.95-1.05) 1.09 (1.03-1.17)*** 1.02 (0.96-1.08)*** 
MAP > 95th percentile, n (%) 159 (4.6) 19 (31.7)*** 20 (5.4) 
    
EFW centile, median (IQR) 53.5 (30.8-75.4) 47.8 (26.3-79.4) 12.2 (4.2-24.5)*** 
EFW < 5th percentile, n (%) 51 (1.5) 4 (6.2)** 104 (27.4)*** 
Table 3. Biochemical and biophysical markers in pregnancies delivering by cesarean section 
for fetal distress and those delivering vaginally. 
 
 
 
PLGF = placental growth factor; sFlt-1 = soluble fms-like tyrosine kinase-1; Ut PI = uterine artery pulsatility index; 
UA PI = umbilical artery pulsatility index; MCA PI = middle cerebral artery pulsatility index; MAP = mean arterial 
pressure; EFW = estimated fetal weight.  Significance value adjusted for multiple comparisons with post hoc 
Bonferonni correction; *p<0.025, ** p<0.01; *** p<0.0001 
 
 
 
 
 
Vaginal delivery 
(n=3,017) 
Cesarean section for fetal distress 
In labour 
(n=275) 
Before labor 
(n=7) 
Biochemical markers    
PlGF (MoM), median (IQR) 0.98 (0.55-1.68) 0.90 (0.49-1.76) 0.34 (0.10-1.36)** 
PlGF < 5th percentile, n (%) 141 (4.7) 25 (9.1)** 4 (57.1)*** 
    
sFlt -1 (MoM), median (IQR) 0.96 (0.73-1.34) 1.08 (0.77-1.44)** 1.91 (1.44-2.87)* 
sFlt > 95th percentile, n (%) 135 (4.5) 17 (6.2) 4 (57.1)*** 
Biophysical markers    
Ut PI (MoM), median (IQR) 0.98 (0.84-1.14) 1.01 (0.85-1.20) 1.65 (1.13-1.85)** 
Ut PI > 95th percentile, n (%) 141 (4.7) 11 (4.0) 4 (57.1)*** 
    
UA PI (MoM), median (IQR) 1.01 (0.90-1.12) 1.02 (0.91-1.12) 1.30 (1.28-1.49)*** 
UA PI > 95th percentile, n (%) 148 (4.9) 12 (4.4) 6 (85.7)*** 
    
MCA PI (MoM), median (IQR) 1.01 (0.90-1.12) 1.00 (0.89-1.14) 0.78 (0.77-0.95)** 
MCA PI < 5th percentile, n (%) 140 (4.6) 12 (4.4) 4 (57.1)*** 
    
MAP (MoM), median (IQR) 1.00 (0.95-1.06) 1.01 (0.96-1.07) 1.08 (0.98-1.18) 
MAP > 95th percentile, n (%) 139 (4.7) 16 (6.0) 3 (42.9)** 
    
EFW centile, median (IQR) 47.9 (24.4-70.7) 55.5 (29.3-76.2)** 0.64 (0.27-2.02)*** 
EFW < 5th percentile, n (%) 127 (4.2) 8 (2.9) 7 (100.0)*** 
Table 4. Biochemical and biophysical markers in pregnancies with and without low cord blood pH, low Apgar score at 5 minutes and admission 
to the neonatal unit. 
 
 
PLGF = placental growth factor; sFlt-1  = soluble fms-like tyrosine kinase-1; Ut PI = uterine artery pulsatility index; UA PI = umbilical artery pulsatility index; MCA PI = middle 
cerebral artery pulsatility index; MAP = mean arterial pressure; EFW = estimated fetal weight.  Significance value adjusted for multiple comparisons with post hoc Bonferonni 
correction ** p<0.01; *** p<0.0001 
 
 
Biomarker 
Umbilical cord pH Apgar Score Admission to NNU 
Unaffected 
(n=1,336) 
Low cord pH 
(n=52) 
Unaffected 
(n=3,586) 
Low Apgar score 
(n=20) 
Unaffected 
(n=3,721) 
NNU admission 
(n=232) 
Biochemical markers       
PlGF (MoM), median (IQR) 0.95 (0.53-1.68) 0.70 (0.43-1.52) 0.96 (0.55-1.67) 1.15 (0.67-2.25) 0.98 (0.55-1.68) 0.94 (0.54-1.71) 
PlGF < 5th percentile, n (%) 81 (6.1) 3 (5.8) 174 (4.9) 0 (0.0) 185 (5.0) 13 (5.6) 
       
sFlt -1 (MoM), median (IQR) 1.01 (0.74-1.42) 1.28 (0.73-1.73) 0.98 (0.74-1.37) 0.99 (0.73-1.16) 0.97 (0.73-1.36) 1.03 (0.75-1.45) 
sFlt > 95th percentile, n (%) 80 (6.0) 7 (13.5) 181 (5.0) 2 (10.0) 183 (4.9) 15 (6.5) 
Biophysical markers       
Ut PI (MoM), median (IQR) 0.99 (0.84-1.17) 1.00 (0.86-1.22) 0.98 (0.83-1.17) 0.98 (0.80-1.20) 0.98 (0.84-1.17) 0.96 (0.83-1.16) 
Ut PI > 95th percentile, n (%) 78 (5.8) 3 (5.8) 178 (5.0) 0 (0.0) 184 (4.9) 14 (6.0) 
       
UA PI (MoM), median (IQR) 1.00 (0.90-1.12) 1.06 (0.94-1.13) 1.01 (0.90-1.12) 1.04 (0.94-1.12) 1.01 (0.90-1.12) 1.02 (0.90-1.12) 
UA PI > 95th percentile, n (%) 64 (4.8) 3 (5.8) 181 (5.0) 0 (0.0) 190 (5.1) 8 (3.4) 
       
MCA PI (MoM), median (IQR) 1.00 (0.90-1.12) 0.96 (0.86-1.07) 1.01 (0.90-1.13) 0.98 (0.86-1.08) 1.01 (0.90-1.12) 1.02 (0.92-1.13) 
MCA PI < 5th percentile, n (%) 60 (4.5) 4 (7.7) 176 (4.9) 2 (10.0) 190 (5.1) 8 (3.4) 
       
MAP (MoM), median (IQR) 1.01 (0.96-1.07) 1.02 (0.99-1.07) 1.01 (0.95-1.06) 1.03 (0.99-1.06) 1.00 (0.95-1.06) 1.02 (0.96-1.08) 
MAP > 95th percentile, n (%) 74 (5.6) 4 (7.7) 174 (5.0) 2 (10.0) 186 (5.1) 12 (5.4) 
       
EFW centile, median (IQR) 54.2 (30.1-76.2) 50.2 (26.4-73.7) 49.7 (25.6-73.2) 59.1 (30.8-67.5) 49.5 (25.6-73.1) 55.5 (28.1-78.6) 
EFW < 5th percentile, n (%) 47 (3.5) 1 (1.9) 136 (3.8) 0 (0.0) 146 (3.9) 13 (5.6) 
